Concepts (66)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 3 | 2011 | 151 | 0.650 |
Why?
|
| Lupus Nephritis | 2 | 2012 | 22 | 0.520 |
Why?
|
| Kidney | 1 | 2012 | 322 | 0.360 |
Why?
|
| Hepatitis | 1 | 2008 | 10 | 0.330 |
Why?
|
| Jaundice | 1 | 2008 | 7 | 0.330 |
Why?
|
| Spondylarthropathies | 1 | 2008 | 2 | 0.330 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2006 | 5 | 0.300 |
Why?
|
| Raynaud Disease | 1 | 2006 | 10 | 0.300 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2008 | 85 | 0.290 |
Why?
|
| Thrombosis | 1 | 2006 | 61 | 0.280 |
Why?
|
| Alzheimer Disease | 2 | 2021 | 881 | 0.220 |
Why?
|
| Genome-Wide Association Study | 2 | 2021 | 271 | 0.220 |
Why?
|
| Puerto Rico | 6 | 2018 | 1352 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2021 | 6 | 0.200 |
Why?
|
| Genetic Variation | 2 | 2021 | 328 | 0.200 |
Why?
|
| Apolipoprotein E4 | 1 | 2018 | 47 | 0.170 |
Why?
|
| Adult | 8 | 2013 | 11034 | 0.150 |
Why?
|
| Female | 9 | 2018 | 19873 | 0.130 |
Why?
|
| Virus Shedding | 1 | 2013 | 9 | 0.120 |
Why?
|
| Personnel, Hospital | 1 | 2013 | 10 | 0.120 |
Why?
|
| Nasal Mucosa | 1 | 2013 | 29 | 0.110 |
Why?
|
| Virus Diseases | 1 | 2013 | 21 | 0.110 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 31 | 0.110 |
Why?
|
| Male | 8 | 2018 | 18870 | 0.110 |
Why?
|
| Humans | 10 | 2021 | 34853 | 0.100 |
Why?
|
| Biopsy | 1 | 2012 | 151 | 0.100 |
Why?
|
| Cyclophosphamide | 1 | 2010 | 52 | 0.090 |
Why?
|
| Young Adult | 4 | 2013 | 4012 | 0.090 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2010 | 52 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 72 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2011 | 159 | 0.090 |
Why?
|
| Disease Progression | 1 | 2011 | 580 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 213 | 0.080 |
Why?
|
| Adolescent | 3 | 2013 | 5035 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2008 | 517 | 0.070 |
Why?
|
| Middle Aged | 3 | 2013 | 9642 | 0.060 |
Why?
|
| Prevalence | 1 | 2008 | 1425 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2010 | 2561 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 2 | 2011 | 137 | 0.050 |
Why?
|
| Genetics, Population | 1 | 2018 | 66 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 338 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2018 | 155 | 0.040 |
Why?
|
| Logistic Models | 2 | 2013 | 894 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2013 | 1422 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2010 | 1349 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1056 | 0.030 |
Why?
|
| Aged | 2 | 2018 | 6448 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2013 | 19 | 0.030 |
Why?
|
| Infection Control | 1 | 2013 | 13 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2013 | 50 | 0.030 |
Why?
|
| Tennessee | 1 | 2013 | 59 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 2333 | 0.030 |
Why?
|
| Influenza, Human | 1 | 2013 | 79 | 0.030 |
Why?
|
| Complement C4 | 1 | 2011 | 5 | 0.030 |
Why?
|
| Proteinuria | 1 | 2011 | 48 | 0.030 |
Why?
|
| Vaccination | 1 | 2013 | 259 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 3414 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 424 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 423 | 0.020 |
Why?
|
| Antirheumatic Agents | 1 | 2010 | 33 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2010 | 80 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 1353 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 707 | 0.020 |
Why?
|
| Comorbidity | 1 | 2010 | 606 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 1007 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2011 | 1961 | 0.020 |
Why?
|